A clinical trial will study the effect of blood plasma transfusions from people younger than 30 on patients with mild to moderate Alzheimer's disease. The study will start in October at the Stanford University School of Medicine. A protein in blood plasma called growth differentiation factor 11, or GDF11, declines with age, and it has been linked with improved brain function in animal studies.

Related Summaries